Compare NTZ & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTZ | VERU |
|---|---|---|
| Founded | 1959 | 1971 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 36.8M |
| IPO Year | 1998 | 1996 |
| Metric | NTZ | VERU |
|---|---|---|
| Price | $2.70 | $2.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 5.5K | ★ 49.2K |
| Earning Date | 04-13-2023 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.15 | $0.36 |
| 52 Week High | $5.50 | $4.59 |
| Indicator | NTZ | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 50.72 | 41.21 |
| Support Level | $2.66 | $2.15 |
| Resistance Level | $3.20 | $2.70 |
| Average True Range (ATR) | 0.27 | 0.11 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 70.14 | 23.53 |
Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.